PATENT CLAIM ANALYSIS

Application Number: 16168632
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Claim (Index 1):
A method of treating allodynia associated with complex regional pain syndrome (CRPS) comprising administering neridronic acid to a human being who is suffering from allodynia associated with CRPS that is triggered by a bone fracture, wherein the method results in a reduction of the allodynia suffered by the human being.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 97.0
- Lexical Diversity: 1.26667
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15647140', '15357932', '15454874', '15710759', '15599319']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8305879748895197
- 35 USC 102 Novelty (BERT): 0.6667512390685622
- Combined Prediction Score: 0.814204301307424
- Mean Citation Score: 581.933676
- Max Citation Score: 595.69556
- Similarity Product: 537.8478640454317

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test